Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

medinova ag - mesalazinum - compresse rivestite con film - mesalazinum 400 mg, excipiens pro compresso obducto. - la colite ulcerosa - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

medinova ag - mesalazinum - compresse rivestite con film - mesalazinum 800 mg, excipiens pro compresso obducto. - la colite ulcerosa - synthetika

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - mesalazinum - suppositorien - mesalazinum 1 g, povidonum, macrogolum 6000, magnesio stearas, talco, per suppositorio. - trattamento attivo ulcerative proctite - synthetika

Italia - Italia - Ministero della Salute

le vet beheer b.v. - carprofen - carprofen - 160 milligrammo (i), carprofen - 40 milligrammo (i), carprofen - 160 mg, carprofen - 40 mg; carprofen - nd - carprofen

Uni Eropa - Italia - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterone acetato - neoplasie prostatiche - terapia endocrina - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Uni Eropa - Italia - EMA (European Medicines Agency)

mylan ireland limited - abiraterone acetato - neoplasie prostatiche - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

opella healthcare italy s.r.l. - bisacodile - bisacodile

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

alfasigma s.p.a. - metronidazolo - metronidazolo

Italia - Italia - AIFA (Agenzia Italiana del Farmaco)

ferring s.p.a. - mesalazina (5-asa) - mesalazina (5-asa)

Swiss - Italia - Swissmedic (Swiss Agency for Therapeutic Products)

tillotts pharma ag - mesalazinum - compressa gastroresistente - mesalazinum 400 mg, lactosum monohydricum 76.4 mg, carboxymethylamylum natricum a corresp. natrium 0.768 mg, magnesii stearas, talcum, povidonum k 25, Überzug: acidi methacrylici et methylis methacrylatis polymerisatum 1:2, talcum, triethylis citras, macrogolum 6000, e 172, pro compresso obducto. - la colite ulcerosa - synthetika